[{"address1": "1560 Trapelo Road", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "781 786 8230", "fax": "781 786 8866", "website": "https://www.dyne-tx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 143, "auditRisk": 7, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 32.39, "open": 32.5, "dayLow": 32.5, "dayHigh": 35.15, "regularMarketPreviousClose": 32.39, "regularMarketOpen": 32.5, "regularMarketDayLow": 32.5, "regularMarketDayHigh": 35.15, "beta": 1.062, "forwardPE": -11.4071665, "volume": 3891823, "regularMarketVolume": 3891823, "averageVolume": 1236829, "averageVolume10days": 1094530, "averageDailyVolume10Day": 1094530, "bid": 34.93, "ask": 35.03, "bidSize": 400, "askSize": 200, "marketCap": 3483005184, "fiftyTwoWeekLow": 6.4, "fiftyTwoWeekHigh": 35.98, "fiftyDayAverage": 28.7615, "twoHundredDayAverage": 19.13065, "currency": "USD", "enterpriseValue": 2633209856, "floatShares": 73161114, "sharesOutstanding": 99457600, "sharesShort": 9355677, "sharesShortPriorMonth": 9023636, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1071, "heldPercentInsiders": 0.00466, "heldPercentInstitutions": 0.98543, "shortRatio": 11.88, "shortPercentOfFloat": 0.1312, "impliedSharesOutstanding": 99457600, "bookValue": 5.489, "priceToBook": 6.380033, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -257399008, "trailingEps": -3.98, "forwardEps": -3.07, "enterpriseToEbitda": -9.966, "52WeekChange": 2.4417691, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "DYN", "underlyingSymbol": "DYN", "shortName": "Dyne Therapeutics, Inc.", "longName": "Dyne Therapeutics, Inc.", "firstTradeDateEpochUtc": 1600349400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bf98e34f-5989-3e23-b14d-e7c60952a6b7", "messageBoardId": "finmb_608699906", "gmtOffSetMilliseconds": -14400000, "currentPrice": 35.02, "targetHighPrice": 56.0, "targetLowPrice": 41.0, "targetMeanPrice": 46.67, "targetMedianPrice": 45.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 453547008, "totalCashPerShare": 5.19, "ebitda": -264208000, "totalDebt": 26617000, "quickRatio": 20.281, "currentRatio": 21.828, "debtToEquity": 5.568, "returnOnAssets": -0.4098, "returnOnEquity": -0.71501, "freeCashflow": -152868368, "operatingCashflow": -219787008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]